Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition

Abstract

The invention relates to peptides and peptide derivatives of the following general Formulas Ia and Ib as well as in particular anti-inflammatory drugs containing these peptides.

1 . Peptide and peptide derivative of the following general Formulas Ia and Ib 
       
         
           
           
               
               
           
         
         wherein: 
         X 1 -X 16  denote one of the 20 genetically encoded amino acids 
         X 17  denotes a residue OR 1 , wherein R 1 =hydrogen or (C 1 -C 10 )-alkyl), or a residue NR 2 R 3 , R 2  and R 3  being identical or different and denoting hydrogen or (C 1 -C 10 )-alkyl, or a residue -PEGS- 5-60K —NR 4 R 5 , R 4  and R 5  being identical or different and hydrogen or (C 1 -C 10 )-alkyl, or a residue NH—CH(CONH 2 )-(CH 2 ) 4 —NH—CO—Y-PEGS- 5-60K , wherein Y may be an oxygen atom or an NH group, or a residue NH—Y—Z-PEGS 5-60K , wherein Y denotes a chemical bond or a genetically coded amino acid from the group of S, C, K or R, and Z denotes a spacer by way of which a polyethylene glycol (PEG)-residue is linked, 
         as well as the physiologically acceptable salts thereof. 
       
     
     
         2 . Peptides and peptide derivates according to  claim 1  of the general Formulas Ia and Ib, wherein:
 X 1 , X 9 , X 10 , X 14  denote L, I, S, M or A,   X 2 , X 6 , X 7  denote E or D,   X 3 , X 4 , X 5 , X 11  denote R or K   X 8 , X 12  denote A, G, S, or L   X 13  denotes I, L or V   X 15 , X 16  denote G, A, S or C   and wherein X 17  has the same meaning as in  claim 1 ,   as well as the physiologically acceptable salts thereof.   
     
     
         3 . Peptides and peptide derivates of Formulas IIa and IIb 
       
         
           
           
               
               
           
         
         wherein X 17  has the same meaning as given for Formula I in  claim 1 , 
         as well as the physiologically acceptable salts thereof. 
       
     
     
         4 . Compounds of the Formulas (IIa) and (IIb) according to  claim 3 , wherein
 X 17  denotes NH 2 , or NR 2 R 3 , R 2  and R 3  being identical or different and denoting hydrogen or (C 1 -C 3 )-alkyl, or a residue -PEG 5-30K —CO—NR 4 R 5 , R 4  and R 5  being the same or different and denoting hydrogen or (C 1 -C 3 )-alkyl, or a residue  NH—CH(CONH   2 )—(CH 2 ) 4 —NH—CO—Y-PEG 5-30K , wherein Y denotes an oxygen atom or an NH group, or a residue C(NR 2 R 3 )-(S-succinimido)-(PEG 5-40K ), the succinimido residue being linked to the sulfur atom of the cysteine residue via C-atom 3,   as well as the physiologically acceptable salts thereof.   
     
     
         5 . (canceled) 
     
     
         6 . A pharmaceutical drug composition, containing a peptide or peptide derivative according to  claim 1 . 
     
     
         7 . A pharmaceutical drug composition, containing a peptide or peptide derivative according to  claim 2 . 
     
     
         8 . A pharmaceutical drug composition, containing a peptide or peptide derivative according to  claim 3 . 
     
     
         9 . A pharmaceutical drug composition, containing a peptide or peptide derivative according to  claim 4 .